Table 3.
Comparison of AKI in patients with HIV to patients without HIV or in whom HIV status was unknown
| No HIV or HIV unknown (n = 63) | HIV (n = 90) | P value | |
|---|---|---|---|
| Demographics | |||
| Age (median; IQR) | 53 (35–71) | 38 (32–46) | 0 · 0004 |
| Male sex | 35 (55 · 6%) | 57 (63 · 3%) | 0 · 334 |
| Primary cause of AKI | |||
| Sepsis and hypoperfusion | 51 (80 · 1%) | 82 (91 · 1%) | 0 · 058a |
| Toxin | 1 (1 · 6%) | 4 (4 · 4%) | |
| Obstruction | 6 (9 · 5%) | 1 (1 · 1%) | |
| Parenchymal Kidney disease | 2 (3 · 2%) | 2 (2 · 2%) | |
| Unclear | 3 (4 · 8%) | 1 (1 · 1%) | |
| AKI Severity | |||
| AKI Stage 3 | 39 (61 · 9%) | 54 (60 · 0%) | 0 · 81 |
| Outcomes | |||
| In-hospital mortality | 22 (37 · 9%) | 42 (48 · 4%) | 0 · 20 |
| Length of stay in days (median; IQR) | 7 · 5 (4–13) | 7 · 5 (5–11) | 0 · 74 |
| Renal recovery (any) | 27 (49 · 1%) | 41 (49 · 4%) | 0 · 97 |
| Persistent kidney injury at dischargeb | 19 (70 · 4%) | 24 (58 · 4%) | 0 · 32 |
AKI acute kidney injury, HIV human immunodeficiency virus
aChi2 test assessing the association of the aetiological category of AKI between groups
bexpressed as a proportion of those with any renal recovery